Wang et al. found that miR-27a promotes ovarian cancer progression through its target FOXO1 [71], while genistein, a nontoxic miR-27a inactivator, can block ovarian cancer cell growth and migration [72]. Here, FOXO1 is linked to ovarian carcinoma.